Mesa Laboratories (NASDAQ:MLAB) Stock Rating Lowered by StockNews.com

Mesa Laboratories (NASDAQ:MLAB) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Wednesday.

Several other brokerages have also commented on MLAB. Wells Fargo & Company started coverage on shares of Mesa Laboratories in a report on Tuesday, August 27th. They issued an “underweight” rating and a $120.00 price objective for the company. Evercore ISI lifted their price target on Mesa Laboratories from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st.

Mesa Laboratories Stock Down 5.5 %

Shares of NASDAQ MLAB opened at $112.40 on Wednesday. The firm has a fifty day simple moving average of $124.09 and a two-hundred day simple moving average of $115.00. Mesa Laboratories has a 12 month low of $82.86 and a 12 month high of $141.17. The company has a current ratio of 1.94, a quick ratio of 1.37 and a debt-to-equity ratio of 1.38. The firm has a market capitalization of $608.08 million, a PE ratio of -2.47 and a beta of 0.87.

Insider Buying and Selling at Mesa Laboratories

In other news, CEO Gary M. Owens sold 2,518 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $113.62, for a total value of $286,095.16. Following the sale, the chief executive officer now directly owns 45,888 shares of the company’s stock, valued at $5,213,794.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, SVP Brian David Archbold sold 1,499 shares of Mesa Laboratories stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $125.00, for a total value of $187,375.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Gary M. Owens sold 2,518 shares of the stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $113.62, for a total transaction of $286,095.16. Following the sale, the chief executive officer now directly owns 45,888 shares in the company, valued at $5,213,794.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Meros Investment Management LP purchased a new position in Mesa Laboratories in the 2nd quarter worth approximately $2,456,000. Keeley Teton Advisors LLC bought a new stake in shares of Mesa Laboratories in the 1st quarter worth $2,606,000. Charles Schwab Investment Management Inc. raised its stake in shares of Mesa Laboratories by 38.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 62,609 shares of the medical instruments supplier’s stock worth $8,130,000 after purchasing an additional 17,450 shares during the last quarter. Eagle Asset Management Inc. lifted its holdings in shares of Mesa Laboratories by 10.9% during the third quarter. Eagle Asset Management Inc. now owns 165,955 shares of the medical instruments supplier’s stock valued at $19,722,000 after purchasing an additional 16,293 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Mesa Laboratories by 7.1% during the second quarter. Dimensional Fund Advisors LP now owns 131,891 shares of the medical instruments supplier’s stock valued at $11,444,000 after buying an additional 8,722 shares during the last quarter. Institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.